Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Total Current Liabilities (2022 - 2025)

Mangoceuticals' Total Current Liabilities history spans 4 years, with the latest figure at $890568.0 for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 37.52% to $890568.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $890568.0, a 37.52% decrease, with the full-year FY2025 number at $890568.0, down 37.52% from a year prior.
  • Total Current Liabilities hit $890568.0 in Q4 2025 for Mangoceuticals, up from $804275.0 in the prior quarter.
  • Over the last five years, Total Current Liabilities for MGRX hit a ceiling of $1.6 million in Q2 2025 and a floor of $159176.0 in Q3 2023.
  • Historically, Total Current Liabilities has averaged $862803.9 across 4 years, with a median of $890568.0 in 2025.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 774.12% in 2024 and later crashed 42.2% in 2025.
  • Tracing MGRX's Total Current Liabilities over 4 years: stood at $260577.0 in 2022, then dropped by 19.0% to $211078.0 in 2023, then skyrocketed by 575.33% to $1.4 million in 2024, then plummeted by 37.52% to $890568.0 in 2025.
  • Business Quant data shows Total Current Liabilities for MGRX at $890568.0 in Q4 2025, $804275.0 in Q3 2025, and $1.6 million in Q2 2025.